274 related articles for article (PubMed ID: 33300601)
1. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors.
Toki MI; Syrigos N; Syrigos K
Int J Cancer; 2021 Jul; 149(2):277-286. PubMed ID: 33300601
[TBL] [Abstract][Full Text] [Related]
2. [Advances in Hyperprogressive Disease in Patients
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
Yao S; Shi K; Zhang Y
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease in patients receiving immune checkpoint inhibitors.
Zhang H; Fang X; Li D; Yang M; Yu L; Ding Y; Shen H; Yuan Y
Curr Probl Cancer; 2021 Jun; 45(3):100688. PubMed ID: 33334611
[TBL] [Abstract][Full Text] [Related]
4. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Park HJ; Kim KW; Won SE; Yoon S; Chae YK; Tirumani SH; Ramaiya NH
JAMA Netw Open; 2021 Mar; 4(3):e211136. PubMed ID: 33760090
[TBL] [Abstract][Full Text] [Related]
5. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.
Wang X; Wang F; Zhong M; Yarden Y; Fu L
Mol Cancer; 2020 May; 19(1):81. PubMed ID: 32359357
[TBL] [Abstract][Full Text] [Related]
6. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
[TBL] [Abstract][Full Text] [Related]
7. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
Chen Y; Hu J; Bu F; Zhang H; Fei K; Zhang P
BMC Cancer; 2020 Jul; 20(1):707. PubMed ID: 32727409
[TBL] [Abstract][Full Text] [Related]
9. Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy.
Wei Z; Zhang Y
Cells; 2022 May; 11(11):. PubMed ID: 35681453
[TBL] [Abstract][Full Text] [Related]
10. Atypical patterns of response and progression in the era of immunotherapy combinations.
Ferrara R; Matos I
Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
[TBL] [Abstract][Full Text] [Related]
11. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
12. Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment.
Li M; Zhong X; Du F; Wu X; Li M; Chen Y; Zhao Y; Shen J; Yang Z; Xiao Z
J Clin Pharmacol; 2022 Sep; 62(9):1059-1078. PubMed ID: 35303368
[TBL] [Abstract][Full Text] [Related]
13. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review.
Liu X; Qiao L
Front Nutr; 2022; 9():810472. PubMed ID: 35399666
[TBL] [Abstract][Full Text] [Related]
15. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
[TBL] [Abstract][Full Text] [Related]
16. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Camelliti S; Le Noci V; Bianchi F; Moscheni C; Arnaboldi F; Gagliano N; Balsari A; Garassino MC; Tagliabue E; Sfondrini L; Sommariva M
J Exp Clin Cancer Res; 2020 Nov; 39(1):236. PubMed ID: 33168050
[TBL] [Abstract][Full Text] [Related]
18. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
19. Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.
Shen P; Han L; Ba X; Qin K; Tu S
Front Pharmacol; 2021; 12():678409. PubMed ID: 34290608
[TBL] [Abstract][Full Text] [Related]
20. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Adashek JJ; Kato S; Ferrara R; Lo Russo G; Kurzrock R
Oncologist; 2020 Feb; 25(2):94-98. PubMed ID: 32043794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
